Sentinel Capital Partners LLC agreed to sell WellSpring Pharma Services Inc., its Canada-based pharmaceutical contract manufacturing organization.

The New York-based private equity firm did not disclose financial terms of the sale.

Sentinel Capital Partners initially invested in WellSpring in 2011. The firm had previously sold WellSpring's consumer healthcare and prescription drug divisions. The sale of WellSpring Pharma Services completes Sentinel's final exit from its original WellSpring investment.

WellSpring Pharma Services provides outsourced manufacturing and contract development services to pharmaceutical and biotechnology companies in the U.S. and Canada.